Insmed (INSM) Cash from Investing Activities Growth (1y) (2011 - 2026)
Powered by 
Analysis
Insmed (INSM) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 91.53% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -41.67% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | -89.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -89.24% |
| Mar 31, 2026 | 230.20% |
| Dec 31, 2025 | 195.55% |
| Sep 30, 2025 | 24.04% |
| Jun 30, 2025 | 3,458.91% |
| Mar 31, 2025 | -72.77% |
| Dec 31, 2024 | 7,207.71% |
| Sep 30, 2024 | -14,140.45% |
| Jun 30, 2024 | 97.53% |
| Mar 31, 2024 | 609.87% |
| Dec 31, 2023 | -91.12% |
| Sep 30, 2023 | -85.54% |
| Jun 30, 2023 | -9,340.63% |
| Mar 31, 2023 | 141.02% |
| Dec 31, 2022 | 139.65% |
| Sep 30, 2022 | 688.24% |
| Jun 30, 2022 | 16.67% |
| Mar 31, 2022 | -8,486.54% |
| Dec 31, 2021 | -3,280.73% |
| Sep 30, 2021 | -1,024.63% |